Table 1 Case of HCC with FC
Reference | Age/sex | Tumor size (cm) | HBV/HCV | AFP (ng/ml) | LVEF (%) | CVP (mmHg) | Treatment | Operative tips | Outcome |
|---|---|---|---|---|---|---|---|---|---|
3 | 24/F | 10.8 | −/− | 50,000 | 58 | 14 | L hepatectomy | All the inflow and outflow vessels were dissected and slung | Dead, 6 months |
4 | 27/F | 22.1 | −/− | 162.7 | ND | ND | 5 FU | Dead, 1 year | |
4 | 28/F | 4 | −/− | Negative | ND | ND | Sorafenib | Dead, 1 year Liver failure | |
5 | 27/F | 2.2 | −/− | 162.7 | ND | ND | Systemic therapy | Dead, 1 year | |
5 | 28/F | 4 | −/− | 788 | ND | ND | Sorafenib | Dead, 1 year | |
6 | 32/F | 4 | −/− | 700 | ND | ND | TACE | Alive | |
6 | 24/M | ND | −/− | 5000 | ND | ND | ND | Dead | |
6 | 33/M | ND | −/− | 630 | ND | ND | Radioembolization | Dead | |
6 | 42/F | ND | −/+ | 106 | ND | ND | TACE | Alive | |
7 | 51/M | 1 | −/− | WNL | ND | ND | Local abration | Alive, 28 months | |
8 | 19/F | ND | −/− | ND | ND | ND | Sorafenib | Dead, 3 months | |
9 | 15/M | ND | −/− | 2 | ND | ND | TAE | Dead, 2 years | |
10 | 16/F | 12.5 | −/− | 211,580 | 59 | ND | Systemic chemotherapy | Dead, 2 months | |
11 | 23/F | 14.8 | ND | ND | ND | ND | Extended R-H | Venovenous bypass | ND |
12 | 32/M | 4 | −/− | 13 | ND | 12–13 | S6 and S7 resection | Pringle maneuver | ND |
13 | 29/F | 1.5 | −/− | 117.1 | ND | ND | S4 wedge resection | Not mentioned | Alive, 1 year |
14 | 24 | ND | −/− | ND | ND | 17 | ND | ND | |
14 | 41 | ND | −/+ | ND | ND | ND | TAE | ND | |
14 | 22 | ND | −/− | ND | ND | 19 | TAE + systemic chemotherapy | ND | |
14 | 29 | ND | −/− | ND | ND | 21 | No indication | Dead | |
14 | 43 | ND | −/− | ND | ND | 13 | TAE + systemic chemotherapy | Dead | |
15 | 13/F | 5 | −/− | 3340 | ND | ND | TAE with lipiodol and doxorubicin eluting microbeads | Alive, 6 months | |
Present case | 37/F | 6.3 | −/− | 81,663 | 56 | 12 | L hepatectomy with caudate lobectomy | rTP and Pringle maneuver | Alive, 16 months with lung metastasis |